Bayer/Orion showcase results from prostate cancer challengerBayer and development partner Orion have released detailed results from the trial that will form the backbone of Share XBayer/Orion showcase results from prostate cancer challengerhttps://pharmaphorum.com/news/bayer-orion-showcase-results-from-prostate-cancer-challenger/
Janssen’s esketamine depression drug set for key panel voteJanssen’s potential depression treatment made from esketamine – a version of the substance notoriously used illegally as a Share XJanssen’s esketamine depression drug set for key panel votehttps://pharmaphorum.com/news/janssens-esketamine-depression-drug-set-for-key-panel-vote/
Sanofi’s Darzalex rival hits the mark in phase 3 trialJohnson & Johnson’s Darzalex multiple myeloma drug has just become a blockbuster – but it could face competition Share XSanofi’s Darzalex rival hits the mark in phase 3 trialhttps://pharmaphorum.com/news/sanofis-darzalex-rival-hits-the-mark-in-phase-3-trial/
Novartis makes quality of life case for Cosentyx with new dataThere is increasing recognition that skin clearance scores may not be enough to win over patients and doctors Share XNovartis makes quality of life case for Cosentyx with new datahttps://pharmaphorum.com/news/novartis-makes-quality-of-life-case-for-cosentyx-with-new-data/
AbbVie and J&J claim new Imbruvica okay in USAbbVie and Johnson & Johnson’s Imbruvica has become the first chemo-free treatment for first-line chronic lymphocytic leukaemia (CLL) Share XAbbVie and J&J claim new Imbruvica okay in UShttps://pharmaphorum.com/news/abbvie-and-jj-claim-new-imbruvica-okay-in-us/
J&J ends 2018 on a high, but coming year looks shakyJohnson & Johnson (J&J) has kicked off results season with a downbeat forecast for the year as competition Share XJ&J ends 2018 on a high, but coming year looks shakyhttps://pharmaphorum.com/news/jj-ends-2018-on-a-high-but-coming-year-looks-shaky/
AbbVie and J&J’s Imbruvica fails pancreatic cancer testAbbVie and Johnson & Johnson’s hopes of adding pancreatic cancer to the repertoire of oncology blockbuster Imbruvica has Share XAbbVie and J&J’s Imbruvica fails pancreatic cancer testhttps://pharmaphorum.com/news/abbvie-and-jjs-imbruvica-fails-pancreatic-cancer-test/
J&J partners with Apple for ECG monitoring projectApple has a new big pharma partner to help put its new Apple Watch with built-in electrocardiogram (ECG) Share XJ&J partners with Apple for ECG monitoring projecthttps://pharmaphorum.com/news/jj-partners-with-apple-for-ecg-monitoring-project/
J&J’s Tremfya outperforms Novartis’ Cosentyx in psoriasisA large head-to-head study has shown Johnson & Johnson’s psoriasis drug Tremfya outperformed Novartis’ rival, Cosentyx, which had Share XJ&J’s Tremfya outperforms Novartis’ Cosentyx in psoriasishttps://pharmaphorum.com/news/jjs-tremfya-outperforms-novartis-cosentyx-in-psoriasis/
